EA201591787A1 - Таблетки совапревира - Google Patents

Таблетки совапревира

Info

Publication number
EA201591787A1
EA201591787A1 EA201591787A EA201591787A EA201591787A1 EA 201591787 A1 EA201591787 A1 EA 201591787A1 EA 201591787 A EA201591787 A EA 201591787A EA 201591787 A EA201591787 A EA 201591787A EA 201591787 A1 EA201591787 A1 EA 201591787A1
Authority
EA
Eurasian Patent Office
Prior art keywords
description
tablets
pvp
crystal growth
growth inhibitor
Prior art date
Application number
EA201591787A
Other languages
English (en)
Inventor
Дженнифер Хсинг-Чхунг Чу
Гаутам Шах
Авинаш Пхадке
Original Assignee
Ачиллион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ачиллион Фармасьютикалз, Инк. filed Critical Ачиллион Фармасьютикалз, Инк.
Publication of EA201591787A1 publication Critical patent/EA201591787A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описание включает ядра таблеток, содержащие совапревир и ингибитор роста кристаллов, выбранный из гидроксипропил метилцеллюлозы (НРМС), НРС (гидроксипропилцеллюлоза), гипромеллозы ацетат-сукцината (HPMCAS), поливинилпирролидона (PVP), коповидона (PVP-VA), сополимера метакриловой кислоты и этилакрилата или любой комбинации из перечисленных компонентов, где соотношение совапревира и ингибитора роста кристаллов составляет от примерно 40:60 (вес./вес.) до примерно 60:40 (вес./вес.). Описание включает также таблетки с пленочным покрытием. Описание включает также способы лечения HCV описанными в тексте таблетками.
EA201591787A 2013-03-15 2014-03-13 Таблетки совапревира EA201591787A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790645P 2013-03-15 2013-03-15
PCT/US2014/025969 WO2014151547A1 (en) 2013-03-15 2014-03-13 Sovaprevir tablets

Publications (1)

Publication Number Publication Date
EA201591787A1 true EA201591787A1 (ru) 2015-12-30

Family

ID=50439520

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591787A EA201591787A1 (ru) 2013-03-15 2014-03-13 Таблетки совапревира

Country Status (12)

Country Link
US (1) US20140271855A1 (ru)
EP (1) EP2968171A1 (ru)
JP (1) JP2016512845A (ru)
KR (1) KR20160005022A (ru)
CN (1) CN105358137A (ru)
AU (1) AU2014233897A1 (ru)
BR (1) BR112015023381A2 (ru)
CA (1) CA2905423A1 (ru)
EA (1) EA201591787A1 (ru)
IL (1) IL241350A0 (ru)
SG (1) SG11201507468TA (ru)
WO (1) WO2014151547A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714343A2 (pt) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
AU2014227849A1 (en) 2013-03-15 2015-10-01 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
CN104258411A (zh) * 2014-09-19 2015-01-07 安徽山河药用辅料股份有限公司 一种硅化微晶纤维素复合辅料及其制备方法
CN105943536A (zh) * 2016-05-06 2016-09-21 杭州容立医药科技有限公司 一种固体分散体的制备方法及其应用
CA3115516C (en) * 2018-10-05 2023-04-25 Isp Investments Llc Smooth high solids film coating composition comprising water soluble cellulose ether, process for preparing the same and method of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2041156T1 (sl) * 2006-07-13 2014-04-30 Achillion Pharmacetuticals, Inc. Peptidi 4-amino-4-oksobutanoila kot inhibitorji virusne replikacije
AR072991A1 (es) * 2008-08-07 2010-10-06 Schering Corp Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida
US8927576B2 (en) * 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor
WO2013116592A1 (en) * 2012-02-01 2013-08-08 Kadmon Pharmaceuticals, Llc Once daily treatment of hepatitis c with ribavirin and taribavirin

Also Published As

Publication number Publication date
WO2014151547A1 (en) 2014-09-25
CN105358137A (zh) 2016-02-24
CA2905423A1 (en) 2014-09-25
SG11201507468TA (en) 2015-10-29
IL241350A0 (en) 2015-11-30
KR20160005022A (ko) 2016-01-13
US20140271855A1 (en) 2014-09-18
JP2016512845A (ja) 2016-05-09
BR112015023381A2 (pt) 2017-07-18
AU2014233897A1 (en) 2015-10-01
EP2968171A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EA201591787A1 (ru) Таблетки совапревира
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12017500720A1 (en) Glycopeptide compositions
JP2016501013A5 (ru)
PE20211976A1 (es) Composiciones de liberacion retardada de linaclotida
PH12017500163A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
MX2018007296A (es) Compuestos de isoindol.
MX2018003497A (es) Formulaciones de aminoacidos de liberacion modificada administradas por via oral.
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
EP3997242A4 (en) METHODS OF DISEASE DETECTION AND RESPONSE TO TREATMENT OF DNAF
EP4414035A3 (en) Combined preparations for the treatment of cancer
IN2015DN04161A (ru)
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
IL292655A (en) Combined therapy of c-c cytokine receptor type 9 (ccr9) inhibitors and integrin-blocking anti-alha4beta7 antibodies
EA201790905A1 (ru) Способ лечения состояний, связанных с рецептором pgi2
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
MX2015012386A (es) Inhibidores de la cinasa cdk9.
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
JP2015044878A5 (ru)
MX2016011182A (es) Liberacion de protones de nitrobenzaldehido para la manipulacion de la acidosis celular.
PH12015502119A1 (en) Sovaprevir tablets
PH12017501466A1 (en) An oral pharmaceutical formulation comprising sustained-release granules containing tamsulosin hydrochloride
TR201203341A2 (tr) Ranolazin sürekli salım tableti.